Barclays analyst Andrew Mok upgraded Oscar Health (OSCR) to Equal Weight from Underweight with a price target of $18, up from $13. The firm sees managed care stocks benefiting in 2026 from the prospects of margin expansion and rotation away from artificial intelligence-related stocks toward “de-rated underperformers.” Oscar is priced attractively as the market is currently over-discounting the negative outcomes from expiring subsidies, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSCR:
- Oscar Health Extends CEO Bertolini Contract and Compensation
- Oscar faces elevated SEP-driven MLR risk in Georgia, says Jefferies
- Oscar Health: Navigating Growth Opportunities Amidst Underwriting Volatility and Policy Uncertainty
- Oscar Health initiated with an Equal Weight at Stephens
- Private Markets: Kalshi announces new funding at $11B valuation